Research Grade Tixagevimab (AZD8895) (DVV00308)

Tixagevimab can be combined with Cilgavimab to form AZD7442. AZD7442 (2, 4 or 16 mg/kg, i.v.) results in a dose-dependent decrease in lung infection titres and viral RNA levels and a significant reduction in infection titers at the 16 mg/kg dose compared to animals at the 2 mg/kg dose in hamsters infected with strain G614 or in hamsters infected with the Omicron variant^[2].